Fmr LLC Decreases Position in Valeant Pharmaceuticals International, Inc. (VRX)

Fmr LLC reduced its stake in shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 97.4% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 56,170 shares of the specialty pharmaceutical company’s stock after selling 2,094,199 shares during the period. Fmr LLC’s holdings in Valeant Pharmaceuticals International were worth $620,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of VRX. OppenheimerFunds Inc. boosted its stake in Valeant Pharmaceuticals International by 17.1% in the first quarter. OppenheimerFunds Inc. now owns 4,489,169 shares of the specialty pharmaceutical company’s stock valued at $49,516,000 after buying an additional 656,116 shares in the last quarter. Mariner Investment Group LLC bought a new stake in Valeant Pharmaceuticals International during the first quarter valued at approximately $1,035,000. Van ECK Associates Corp boosted its stake in Valeant Pharmaceuticals International by 130.9% in the first quarter. Van ECK Associates Corp now owns 497,272 shares of the specialty pharmaceutical company’s stock valued at $5,485,000 after buying an additional 281,933 shares in the last quarter. WMS Partners LLC bought a new stake in Valeant Pharmaceuticals International during the first quarter valued at approximately $116,000. Finally, BB&T Securities LLC boosted its stake in Valeant Pharmaceuticals International by 29.1% in the first quarter. BB&T Securities LLC now owns 35,632 shares of the specialty pharmaceutical company’s stock valued at $393,000 after buying an additional 8,037 shares in the last quarter. 51.14% of the stock is currently owned by institutional investors and hedge funds.

Shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) opened at 15.37 on Tuesday. Valeant Pharmaceuticals International, Inc. has a one year low of $8.31 and a one year high of $32.74. The company’s market cap is $5.35 billion. The company’s 50 day moving average is $16.16 and its 200 day moving average is $13.34.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.87 by $1.93. Valeant Pharmaceuticals International had a negative net margin of 14.96% and a positive return on equity of 58.02%. The business had revenue of $2.11 billion during the quarter, compared to the consensus estimate of $2.17 billion. During the same quarter last year, the company posted ($1.08) earnings per share. The firm’s quarterly revenue was down 11.1% compared to the same quarter last year. On average, equities analysts predict that Valeant Pharmaceuticals International, Inc. will post $3.89 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Fmr LLC Decreases Position in Valeant Pharmaceuticals International, Inc. (VRX)” was first published by Markets Daily and is owned by of Markets Daily. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.themarketsdaily.com/2017/08/08/fmr-llc-decreases-position-in-valeant-pharmaceuticals-international-inc-vrx.html.

VRX has been the topic of several recent research reports. BidaskClub lowered shares of Valeant Pharmaceuticals International from a “hold” rating to a “sell” rating in a research note on Sunday. Canaccord Genuity set a $14.00 price target on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research note on Friday. Royal Bank Of Canada lifted their price target on shares of Valeant Pharmaceuticals International from $19.00 to $21.00 and gave the company a “sector perform” rating in a research note on Thursday, August 3rd. Wells Fargo & Company dropped coverage on shares of Valeant Pharmaceuticals International in a research note on Sunday, July 30th. Finally, Cantor Fitzgerald set a $23.00 price target on shares of Valeant Pharmaceuticals International and gave the company a “buy” rating in a research note on Friday, July 28th. Four research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $16.96.

In related news, Director Schutter Richard U. De acquired 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 11th. The stock was acquired at an average price of $13.90 per share, for a total transaction of $278,000.00. Following the completion of the acquisition, the director now owns 70,572 shares of the company’s stock, valued at approximately $980,950.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 5.87% of the company’s stock.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply